Get In-depth Biotech Coverage with Timmerman Report.
14
Apr
2026
PhaseV Steps Up for Young Cancer Researchers
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has a new major sponsor.
PhaseV, the Boston-based company which provides AI/ML solutions to speed up and automate key aspects of clinical trials, has agreed to contribute $50,000 as the “Mt. Emerson” sponsor of this summer’s expedition in the High Sierras of California.
This sponsorship could add up to much more. PhaseV has agreed to contribute an additional 5 percent of its net revenues from new oncology-related work in the second quarter of 2026.
This is a creative and generous gift to the next generation of scientists.
Hamza Sheikh, a vice president of business and corporate development at PhaseV, will join the team of biotech executives, investors, and scientists on the trails to Bishop Pass and Piute Pass, Aug. 2-5.

Raviv Pryluk, CEO, PhaseV
“The Timmerman Traverse represents endurance and collaboration, values which are central to conquering cancer. At PhaseV, we apply that same spirit to clinical development,” said Raviv Pryluk, PhD, CEO and co-founder of PhaseV, in a statement. “We are thrilled to cheer on Hamza and his fellow leaders as they trek to help oncology breakthroughs move past development bottlenecks and reach patients faster.”
The team has already raised $243,815 in closed and pending donations, and we have almost four months left in the campaign.
We all know academic science has gone through a tumultuous year with uncertain support from the National Institutes of Health. Young scientists seeking to advance their research ideas have been particularly vulnerable. Damon Runyon focuses on the best young scientists in the US and gives them the vital — and stable — resources to test high-risk/high-reward ideas that move fields forward.

Yung Lie, president and CEO, Damon Runyon Cancer Research Foundation
“We are thrilled to have PhaseV join this summer’s Traverse. Their generous support will directly enable our brave and bold scientists to pursue paradigm-shifting ideas, rather than more incremental research,” said Yung S. Lie, PhD, Damon Runyon’s President and CEO. “Technologies that improve clinical development are crucial for turning breakthrough ideas to reality.”
The Timmerman Traverse has raised more than $3 million for Damon Runyon since 2023, with 100 percent of the proceeds going to support the young scientists.
Here’s a current list of people and projects supported by the Traverse the past three years:
- Tata Kavlashvili PhD, Memorial Sloan Kettering Cancer Center, mitochondrial damage as a driver of cancer.
- Shaohua Zhang PhD, UCSF, improved CAR-T cell engineering to prevent tumor escape
- Lachelle Weeks MD, PhD, Dana Farber Cancer Institute, computer models to predict risk of developing acute myeloid leukemia
- Antonio Laporte PhD, Harvard Medical School, role of glycosylation patterns in driving growth and spread of cancer.
- Natasha O’Brown PhD, Rutgers University, regulating the blood-brain barrier to pave the way for more effective brain cancer therapy.
Sponsors:


This year’s hiking team is composed of 16 men and women from around the country who share a love of the outdoors, personal challenges, and a determination to do what we can to support science.
The team includes:
- Luke Timmerman, founder & editor, Timmerman Report
- Colin Magowan, vice president, business development, Pliant Therapeutics
- Mark Murcko, co-founder, Dewpoint Therapeutics & Relay Therapeutics
- Nadav Rosenberg, investor, Saras Capital
- Lisa Purcell, entrepreneur in residence, Third Rock Ventures
- David Kaufman, partner, Third Rock Ventures
- Rob Crummet, VP, clinical trial management, Kura Oncology
- Michele LeSueur, VP, sales & marketing, hematology, Johnson & Johnson
- Carl Schoellhammer, partner, DeciBio
- Tony Martignetti, chief illumination officer, Inspired Purpose Partners
- Krysta Pellegrino, senior director, R&D communications, Madrigal Pharmaceuticals
- Thomas (Gus) Gustafson, chief scientific officer, Renasant Bio
- Vivek Mittal, partner and head of biopharma, Health Advances
- Anne Kasmar, senior vice president, immunology and infectious disease, Parexel
- Henry Kilgore, assistant professor, nanomedicine and chemical biology, University of British Columbia (*former Damon Runyon Fellow*)
- Hamza Sheikh, vice president of business and corporate development, PhaseV
One more young scientist from the Damon Runyon network will be named to the hiking roster later this spring.
This is all about two-way learning. It’s a great opportunity for a postdoctoral researcher to expand his or her network with industry contacts, and for industry leaders to get in touch with what’s happening in cutting-edge research labs. This is a rare and valuable form of bridge building between academia and industry.
If you are interested in joining us on the Traverse Aug. 2-5, or your company is interested in sponsoring this 2026 expedition, send me a note at luke@timmermanreport.com and CC Elyse Hoffmann at Damon Runyon. Elyse.hoffmann@damonrunyon.org.
Let’s invest in the future of science and the biotech industry.























